S&P Global Market Intelligence

Complimentary Report: Panjiva Supply Chain Intelligence

Panjiva Alerts on Mylan's Off-Patent Shipments of Copaxone

Leading Indicator of FDA Approval and 21% Stock Move on October 4, 2017

Shipment activity and supply chain insights can extend beyond what may be immediately obvious to investors and managed care professionals. Download this recent case study to understand how Panjiva data was used to identify shipments to generic pharmaceutical companies of name-brand drugs coming off patent, signalling FDA approval was expected ahead of the announcement.

Panjiva's pharmaceutical sector data surfaces shipment activity, and resolves and links entities across datasets. This sector-specific data package sets the foundation for benchmarking industry activity and providing insights into market share, market entry, patent challenges, and inventory activities of generic drug manufacturers.

Learn more about Panjiva Supply Chain data >>

Praesent porttitor malesuada ornare. Etiam pellentesque vitae risus in elementum. Vivamus ex sem, maximus in ligula vitae, dictum luctus felis. Etiam et rutrum mauris, congue hendrerit nisi. Aenean lorem sem, consequat sit amet diam ut, pellentesque aliquet ante. Ut egestas massa mi, nec condimentum ipsum suscipit non. Interdum et malesuada fames ac ante ipsum primis in faucibus.

Complimentary Report: Panjiva Supply Chain Intelligence

Download the report:

Form Header